Table 1.
Characteristics of the training sample
| Characteristic | RA (n=301) | Non-RA (n=526) |
|---|---|---|
| Age (years), mean (SD) | 66.8 (13.1) | 57.7 (15.7) |
| Female gender, n (%) | 218 (72.4) | 405 (77) |
| Disease duration <2 years, n (%) | 81* (27.6) | |
| Rheumatoid factor positive, n (%) | 151† (54.4) | |
| NSAID or COX-2 inhibitor, n (%) | 198 (65.8) | 298 (56.7) |
| Glucocorticoids, n (%) | 228 (75.8) | 178 (33.8) |
| DMARDs | ||
| Methotrexate, n (%) | 182 (60.5) | 31 (5.9) |
| Antimalarials, n (%) | 153 (50.8) | 67 (12.7) |
| Sulfasalazine, n (%) | 14 (4.7) | 24 (4.6) |
| Leflunomide, n (%) | 12 (4) | 0 (0) |
| Other DMARDs, n (%) | 5 (1.7) | 7 (1.3) |
| Any DMARD, n (%) | 271 (90) | 114 (21.7) |
| Biologics | 30 (10) | 7 (1.3) |
*Data available on 293 participants.
†Data available on 277 participants.
DMARD, disease-modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis.